Paratek Pharmaceuticals, Inc. Sustainability Profile
Paratek Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for serious infections. Founded in 1996, Paratek has made significant strides in the industry, particularly in the field of antibiotic development. The company is renowned for its unique approach to tackling multi-drug resistant pathogens, with core products such as omadacycline and sarecycline, which offer distinct advantages in treating bacterial infections. With a strong presence in both the US and international markets, Paratek has established itself as a key player in the pharmaceutical landscape. The company’s commitment to addressing unmet medical needs has garnered recognition, positioning it as a pioneer in the fight against antibiotic resistance. Paratek Pharmaceuticals continues to advance its mission, striving to deliver effective solutions that improve patient outcomes.
DitchCarbon Score
How does Paratek Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Paratek Pharmaceuticals, Inc.'s score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Paratek Pharmaceuticals, Inc.'s reported carbon emissions
Paratek Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that Paratek Pharmaceuticals may not yet have established a comprehensive framework for addressing its carbon footprint or climate impact. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for Paratek to consider developing and communicating its climate commitments to align with industry standards and expectations.
How Carbon Intensive is Paratek Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Paratek Pharmaceuticals, Inc.'s Location?
Paratek Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Paratek Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
